Stockreport

Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency [Yahoo! Finance]

Palatin Technologies, Inc.  (PTN) 
NASDAQ:AMEX Investor Relations: palatin.com/investors/overview
PDF CRANBURY, N.J. March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on [Read more]